Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma
Authors:
- Hideki IwamotoHIHideki Iwamoto
- Takashi NiizekiTNTakashi Niizeki
- Hiroaki NagamatsuHNHiroaki Nagamatsu
- Kazuomi UeshimaKUKazuomi Ueshima
- Takako NomuraTNTakako Nomura
- Teiji KuzuyaTKTeiji Kuzuya
- Kazuhiro KasaiKKKazuhiro Kasai
- Yohei KookaYKYohei Kooka
- Atsushi HiraokaAHAtsushi Hiraoka
- Rie SugimotoRSRie Sugimoto
- Takehiro YonezawaTYTakehiro Yonezawa
- Akio IshiharaAIAkio Ishihara
Open Access
Abstract
BACKROUND: Not all patients with hepatocellular carcinoma (HCC) benefit from treatment with molecular targeted agents such as sorafenib. We investigated whether New-FP (fine-powder cisplatin and 5-fluorouracil), a hepatic arterial infusion chemotherapy regimen, is more favorable than sorafenib as an initial treatment for locally progressed HCC. METHODS: To avoid selection bias, we corrected the data from different facilities that did or did not perform New-FP therapy. In total, 1709 consecutive patients with HCC initially treated with New-FP or sorafenib; 1624 (New-FP, n = 644; sorafenib n = 980) were assessed. After propensity score matching (PSM), overall survival (OS) and prognostic factors were assessed (n = 344 each). Additionally, the patients were categorized into four groups: cohort-1 [(without macrovascular invasion (MVI) and extrahepatic spread (EHS)], cohort-2 (with MVI), cohort-3 (with EHS), and cohort-4 (with MVI and EHS) to clarify the efficacy of each treatment. RESULTS: New-FP prolonged OS than sorafenib after PSM (New-FP, 12 months; sorafenib, 7.9 months; p < 0.001). Sorafenib treatment, and severe MVI and EHS were poor prognostic factors. In the subgroup analyses, the OS was significantly longer the New-FP group in cohort-2. CONCLUSIONS: Local treatment using New-FP is a potentially superior initial treatment compared with sorafenib as a multidisciplinary treatment in locally progressed HCC without EHS.Keywords
This publication has 42 references indexed in Scilit:
- Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapyJournal of Gastroenterology, 2012
- Hepatic arterial infusion chemotherapy using 5‐fluorouracil and systemic interferon‐α for advanced hepatocellular carcinoma in combination with or without three‐dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cavaHepatology Research, 2011
- Randomized, Phase II Study Comparing Interferon Combined with Hepatic Arterial Infusion of Fluorouracil plus Cisplatin and Fluorouracil Alone in Patients with Advanced Hepatocellular CarcinomaOncology, 2011
- Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated VersionDigestive Diseases, 2011
- Intra‐arterial therapy with cisplatin suspension in lipiodol and 5‐fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosisAlimentary Pharmacology & Therapeutics, 2010
- Hepatic Arterial Infusion Chemotherapy Using Low-Dose 5-Fluorouracil and Cisplatin for Advanced Hepatocellular CarcinomaOncology, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapyJournal of Gastroenterology, 2005
- Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosisCancer, 2002
- Prognosis of Hepatocellular Carcinoma: The BCLC Staging ClassificationSeminars in Liver Disease, 1999